Discussions Around the DeLLphi-305 Trial
Sevabertinib Moves Into First-Line HER2-Mutant NSCLC With FDA Accelerated Approval
FDA Expands Accelerated Approval of Sevabertinib for HER2-Mutant Non-small Cell Lung Cancer
Benjamin L. Ebert: A Major Step Forward for Personalized Cancer Vaccines
MOB-RT Supports Moderate Hypofractionated Pelvic Radiotherapy in High-Risk Prostate Cancer
Vanessa Kerry։ Honored to Have Been Appointed as the Director-General's Special Envoy for Health Resilience
Gilberto Lopes: DeLLphi-305 Signals a Potential Shift in First-Line SCLC
Hodgkin Lymphoma in 2026: What the New EHA Guidelines Recommend
